[Public Notice+] SuzenTech Registers Patent for 'Wuhan Pneumonia' Rapid Diagnostic Kit Technology: "Development of Fluorescent Standard Strip Technology"

[Asia Economy Reporter Hyunseok Yoo] Suzentec announced on the 3rd that it has completed the patent registration for the ‘Fluorescent Standard Strip’ technology for rapid diagnosis of infectious disease diagnostic kits such as ‘Wuhan Pneumonia’.

The newly registered ‘Fluorescent Standard Strip’ technology is a foundational technology used in rapid diagnostic kits for infectious diseases such as pulmonary tuberculosis, influenza, as well as emergency diseases including inflammation and cardiovascular conditions. It allows various diagnostic kits to be measured with a single on-site analyzer, which is expected to aid active quarantine efforts through rapid testing.

A company representative explained, “Suzentec’s currently developing ‘Wuhan Pneumonia specialized diagnostic kit’ is being developed based on the ‘Fluorescent Standard Strip’ technology,” and added, “With this patent registration, Suzentec’s technological superiority related to rapid diagnostic kits for pulmonary tuberculosis, influenza, inflammation, and cardiovascular diseases has been externally confirmed.”

The Wuhan Pneumonia diagnostic kit under development by Suzentec utilizes a blood-centered diagnostic platform to determine pneumonia infection status within about 20 minutes. Unlike the previously used pan-coronavirus testing method, which requires a two-step process and takes 1 to 2 days to deliver results, Suzentec’s rapid diagnostic kit can diagnose infection status in about 20 minutes, enabling prompt response.

The company representative stated, “To prevent the spread of Wuhan Pneumonia, an accurate and rapid method for suspected infected patients is necessary, but diagnostic kits are globally insufficient, often resulting in symptomatic individuals being classified without confirmation,” and added, “With the completion of domestic patent registration, we plan to accelerate commercialization.”

Meanwhile, Suzentec recently signed a memorandum of understanding (MOU) with Humanwell Healthcare Group, headquartered in Wuhan, China, to develop a rapid diagnostic kit for the novel coronavirus infection (Wuhan Pneumonia) and is proceeding with development.

This content was produced with the assistance of AI translation services.